Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism

Hsei Wei Wang, Shung Haur Yang, Guan Da Huang, Jen Kou Lin, Wei Shone Chen, Jeng Kai Jiang, Yuan Tzu Lan, Chun Chi Lin, Wei Lun Hwang, Cheng Hwai Tzeng, Anna Fen Yau Li, Chueh Chuan Yen, Hao Wei Teng

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: A dozen clinical trials examining a combination of temsirolimus and cetuximab in treating metastatic colon cancer are currently underway. We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer. Methods: Five colon cancer cell lines were used for in vitro studies. Signal transduction pathways were assessed by immunoblotting. The synergism between studied drugs was analyzed with combination indexes. Gene silencing was performed using small interfering RNAs. The efficacies of temsirolimus and cetuximab were tested in nude mice with colon cancer xenografts. Transcriptional activity was assessed using a reporter assay. The inhibitors leupeptin, chloroquine, and MG132 were used to assess protein degradation. The association between CIP2A, clinicopathological parameters, and survival was examined by immunohistochemical staining using a tumor tissue microarray. Results: Temsirolimus decreased the resistance of cells to cetuximab by both inhibiting transcription of CIP2A and increasing degradation of CIP2A through the lysosomal-autophagy pathway. The mammalian target of rapamycin (mTOR) protein immunoprecipitated along with CIP2A. Temsirolimus decreased expression of phosphorylated extracellular regulated protein kinase (pErk) and phosphorylated v-akt murine thymoma viral oncogene (pAKT) and decreased the interaction of CIP2A and mTOR in cell lines without the K-ras codon 12 mutation. CIP2A was a prognostic marker only in colon cancer patients with weak expression of pErk or pAKT. Conclusions: Temsirolimus decreases cellular resistance to cetuximab by regulating CIP2A expression in colon cancer cells. Potential biomarkers for CIP2A inhibitors include pErk and pAKT.

Original languageEnglish
Pages (from-to)561-571
Number of pages11
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Protein Phosphatase 2
Colonic Neoplasms
Protein Kinases
TOR Serine-Threonine Kinases
Cetuximab
temsirolimus
Cell Line
Thymoma
Autophagy
Chloroquine
Gene Silencing
Sirolimus
Oncogenes
Immunoblotting
Heterografts
Nude Mice
Codon
Small Interfering RNA
Proteolysis
Signal Transduction

Keywords

  • AKT
  • Autophagy
  • Erk
  • mTOR

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. / Wang, Hsei Wei; Yang, Shung Haur; Huang, Guan Da; Lin, Jen Kou; Chen, Wei Shone; Jiang, Jeng Kai; Lan, Yuan Tzu; Lin, Chun Chi; Hwang, Wei Lun; Tzeng, Cheng Hwai; Li, Anna Fen Yau; Yen, Chueh Chuan; Teng, Hao Wei.

In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 4, 2014, p. 561-571.

Research output: Contribution to journalArticle

Wang, HW, Yang, SH, Huang, GD, Lin, JK, Chen, WS, Jiang, JK, Lan, YT, Lin, CC, Hwang, WL, Tzeng, CH, Li, AFY, Yen, CC & Teng, HW 2014, 'Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism', Journal of Cancer Research and Clinical Oncology, vol. 140, no. 4, pp. 561-571. https://doi.org/10.1007/s00432-014-1596-4
Wang, Hsei Wei ; Yang, Shung Haur ; Huang, Guan Da ; Lin, Jen Kou ; Chen, Wei Shone ; Jiang, Jeng Kai ; Lan, Yuan Tzu ; Lin, Chun Chi ; Hwang, Wei Lun ; Tzeng, Cheng Hwai ; Li, Anna Fen Yau ; Yen, Chueh Chuan ; Teng, Hao Wei. / Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. In: Journal of Cancer Research and Clinical Oncology. 2014 ; Vol. 140, No. 4. pp. 561-571.
@article{51eedd4d97f345b3b71c46b347d7bb80,
title = "Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism",
abstract = "Purpose: A dozen clinical trials examining a combination of temsirolimus and cetuximab in treating metastatic colon cancer are currently underway. We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer. Methods: Five colon cancer cell lines were used for in vitro studies. Signal transduction pathways were assessed by immunoblotting. The synergism between studied drugs was analyzed with combination indexes. Gene silencing was performed using small interfering RNAs. The efficacies of temsirolimus and cetuximab were tested in nude mice with colon cancer xenografts. Transcriptional activity was assessed using a reporter assay. The inhibitors leupeptin, chloroquine, and MG132 were used to assess protein degradation. The association between CIP2A, clinicopathological parameters, and survival was examined by immunohistochemical staining using a tumor tissue microarray. Results: Temsirolimus decreased the resistance of cells to cetuximab by both inhibiting transcription of CIP2A and increasing degradation of CIP2A through the lysosomal-autophagy pathway. The mammalian target of rapamycin (mTOR) protein immunoprecipitated along with CIP2A. Temsirolimus decreased expression of phosphorylated extracellular regulated protein kinase (pErk) and phosphorylated v-akt murine thymoma viral oncogene (pAKT) and decreased the interaction of CIP2A and mTOR in cell lines without the K-ras codon 12 mutation. CIP2A was a prognostic marker only in colon cancer patients with weak expression of pErk or pAKT. Conclusions: Temsirolimus decreases cellular resistance to cetuximab by regulating CIP2A expression in colon cancer cells. Potential biomarkers for CIP2A inhibitors include pErk and pAKT.",
keywords = "AKT, Autophagy, Erk, mTOR",
author = "Wang, {Hsei Wei} and Yang, {Shung Haur} and Huang, {Guan Da} and Lin, {Jen Kou} and Chen, {Wei Shone} and Jiang, {Jeng Kai} and Lan, {Yuan Tzu} and Lin, {Chun Chi} and Hwang, {Wei Lun} and Tzeng, {Cheng Hwai} and Li, {Anna Fen Yau} and Yen, {Chueh Chuan} and Teng, {Hao Wei}",
year = "2014",
doi = "10.1007/s00432-014-1596-4",
language = "English",
volume = "140",
pages = "561--571",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism

AU - Wang, Hsei Wei

AU - Yang, Shung Haur

AU - Huang, Guan Da

AU - Lin, Jen Kou

AU - Chen, Wei Shone

AU - Jiang, Jeng Kai

AU - Lan, Yuan Tzu

AU - Lin, Chun Chi

AU - Hwang, Wei Lun

AU - Tzeng, Cheng Hwai

AU - Li, Anna Fen Yau

AU - Yen, Chueh Chuan

AU - Teng, Hao Wei

PY - 2014

Y1 - 2014

N2 - Purpose: A dozen clinical trials examining a combination of temsirolimus and cetuximab in treating metastatic colon cancer are currently underway. We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer. Methods: Five colon cancer cell lines were used for in vitro studies. Signal transduction pathways were assessed by immunoblotting. The synergism between studied drugs was analyzed with combination indexes. Gene silencing was performed using small interfering RNAs. The efficacies of temsirolimus and cetuximab were tested in nude mice with colon cancer xenografts. Transcriptional activity was assessed using a reporter assay. The inhibitors leupeptin, chloroquine, and MG132 were used to assess protein degradation. The association between CIP2A, clinicopathological parameters, and survival was examined by immunohistochemical staining using a tumor tissue microarray. Results: Temsirolimus decreased the resistance of cells to cetuximab by both inhibiting transcription of CIP2A and increasing degradation of CIP2A through the lysosomal-autophagy pathway. The mammalian target of rapamycin (mTOR) protein immunoprecipitated along with CIP2A. Temsirolimus decreased expression of phosphorylated extracellular regulated protein kinase (pErk) and phosphorylated v-akt murine thymoma viral oncogene (pAKT) and decreased the interaction of CIP2A and mTOR in cell lines without the K-ras codon 12 mutation. CIP2A was a prognostic marker only in colon cancer patients with weak expression of pErk or pAKT. Conclusions: Temsirolimus decreases cellular resistance to cetuximab by regulating CIP2A expression in colon cancer cells. Potential biomarkers for CIP2A inhibitors include pErk and pAKT.

AB - Purpose: A dozen clinical trials examining a combination of temsirolimus and cetuximab in treating metastatic colon cancer are currently underway. We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer. Methods: Five colon cancer cell lines were used for in vitro studies. Signal transduction pathways were assessed by immunoblotting. The synergism between studied drugs was analyzed with combination indexes. Gene silencing was performed using small interfering RNAs. The efficacies of temsirolimus and cetuximab were tested in nude mice with colon cancer xenografts. Transcriptional activity was assessed using a reporter assay. The inhibitors leupeptin, chloroquine, and MG132 were used to assess protein degradation. The association between CIP2A, clinicopathological parameters, and survival was examined by immunohistochemical staining using a tumor tissue microarray. Results: Temsirolimus decreased the resistance of cells to cetuximab by both inhibiting transcription of CIP2A and increasing degradation of CIP2A through the lysosomal-autophagy pathway. The mammalian target of rapamycin (mTOR) protein immunoprecipitated along with CIP2A. Temsirolimus decreased expression of phosphorylated extracellular regulated protein kinase (pErk) and phosphorylated v-akt murine thymoma viral oncogene (pAKT) and decreased the interaction of CIP2A and mTOR in cell lines without the K-ras codon 12 mutation. CIP2A was a prognostic marker only in colon cancer patients with weak expression of pErk or pAKT. Conclusions: Temsirolimus decreases cellular resistance to cetuximab by regulating CIP2A expression in colon cancer cells. Potential biomarkers for CIP2A inhibitors include pErk and pAKT.

KW - AKT

KW - Autophagy

KW - Erk

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=84899487573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899487573&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1596-4

DO - 10.1007/s00432-014-1596-4

M3 - Article

C2 - 24493623

AN - SCOPUS:84899487573

VL - 140

SP - 561

EP - 571

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -